| 词条 | Thomas Hutson |
| 释义 |
| name = Thomas Hutson | image = Thomas Hutson.jpeg | nationality = American | alma_mater = Ohio Northern University Ohio University Heritage College of Medicine }}Thomas E. Hutson is an American medical oncologist and cancer researcher based in Dallas, Texas. He is the director of Genitourinary Oncology Program and co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center.[1] He is a Professor of Medicine at the Texas A&M Health Science Center College of Medicine and serves as a chair of Genitourinary Research for US Oncology and McKesson.[2] Most of Hutson’s research has been focused on using novel and targeted treatments for improving the outcome in patients with renal cell carcinoma.[3][4] As an expert in his field,[5][6] he has served as the principal investigator on several international clinical trials on novel therapies in renal cell carcinoma, bladder cancer, and prostate cancer.[7][8] In addition, he has authored over 500 scholarly academic and research papers.[9] EducationIn 1993, Hutson completed his bachelor's degree in Pharmacy from the Ohio Northern University. He received his Doctor of Osteopathic Medicine (D.O.) degree from the Ohio University Heritage College of Osteopathic Medicine in 1997. And, in 2002 he received his Doctor of Pharmacy degree from Ohio Northern University.[10] CareerIn 1997, he joined the Cleveland Clinic Foundation to complete his internship and residency. Alongside a clinical fellowship in Hematology and Medical Oncology and a fellowship in Experimental Therapeutics, he joined the Ohio Northern University for Ph.D. in Pharmacy, which he completed in 2002.[11] Hutson became a Professor of Pharmacy at Raabe College of Pharmacy, Ohio Northern University in 2001 and taught there till 2008. In 2012, he joined Texas A&M Health Science Center College of Medicine as Professor of Medicine.[12] In 2006, he became the Chair and Medical Director at Genitourinary Research Committee at US Oncology Research and McKesson, a position where he served till 2015 when he became the Associate Chair of the Committee. In 2011, Hutson was appointed as the Co-Director of the Urologic Cancer Research and Treatment Center at Baylor’s Sammons Cancer Center.[13] In 2014, Hutson started religious studies at the Dallas Theological Seminary with a ministry focused on understanding the relationship between religion and medicine specifically focused on Christian Spirituality at End-of-life. He serves as a medical director for Holy Savior Hospice.[14] Hutson serves on the editorial boards of Clinical Prostate Cancer, Expert Review of Anticancer Therapy, Cancer.NET as well as Clinical Genitourinary Cancer. He is also the reviewer for several other journals including New England Journal of Medicine, The Lancet and Lancet Oncology. Since 2004, he has served on the Medical Advisory board of Kidney Cancer Association.[15] Hutson is a member of the American Society of Clinical Oncology, European Society of Medical Oncology, Society of Urologic Oncology, American Medical Association, American Society of Hematology, and the American College of Physicians.[16] He is regularly invited speaker at medical conferences around the world.[17][18] Awards
Partial bibliography
References1. ^Inlyta Falls Short in Kidney Cancer {{DEFAULTSORT:Hutson, Thomas}}2. ^Management of Treatment-Related Toxicities for Metastatic RCC 3. ^Hedefi 12'den vuruyor 4. ^Yeni umut Kanserajan 5. ^Targeted therapy for the treatment of advanced renal cell carcinoma 6. ^Immunotherapy Combinations for Renal Cell Carcinoma Offer Promise, Challenges 7. ^New trial results on pazopanib have important implications for patients with advanced renal cell carcinoma 8. ^Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma 9. ^Randomized Phase II Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma 10. ^Overview 11. ^Overview 12. ^HUTSON, THOMAS, D.O., PHARM.D. 13. ^{{cite journal| pmid=21346036 | doi=10.1634/theoncologist.2011-S2-14 | pmc=3868199 | volume=16 Suppl 2 | title=Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence | year=2011 | journal=Oncologist | pages=14–22 | last1 = Hutson | first1 = TE}} 14. ^HUTSON, THOMAS, D.O., PHARM.D. 15. ^HUTSON, THOMAS, D.O., PHARM.D. 16. ^Medical Advisors 17. ^PFS Not Significantly Better With First-Line Axitinib Versus Sorafenib in mRCC 18. ^Management of Toxicities Related to Systemic Targeted Therapy for mRCC- Hutson 19. ^Thomas Hutson, D.O. 20. ^Contemporary Therapeutic Strategies for Untreated Advanced RCC: A new paradigm 21. ^Evolution of individualized patient care in metastatic kidney cancer 4 : American medical researchers|American oncologists|Living people|Year of birth missing (living people) |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。